Physician profile
Daniel C Rabb
NPI 1194713016
$7,191.44
in general payments reported to CMS, 2019-2025
33 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $183 · 2021: $683 · 2022: $1,658 · 2023: $1,393 · 2024: $1,333 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,014.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,697.49 | 2019-2025 | |
| Genzyme Corporation | $1,373.25 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $444.60 | 2022-2025 | Sotyktu |
| Pfizer INC. | $429.88 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $409.72 | 2019-2024 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $328.54 | 2019-2025 | Tremfya, Stelara, Simponi |
| Dermavant Sciences, INC. | $325.44 | 2022-2024 | Vtama |
| Incyte Corporation | $280.66 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $278.43 | 2019-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $260.00 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $250.64 | 2019-2025 | Jublia |
| Lilly USA, LLC | $178.52 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Leo Pharma INC. | $143.85 | 2024-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $136.46 | 2025 | Nemluvio |
| Genentech USA, INC. | $106.04 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $71.02 | 2023 | |
| Organon LLC | $68.09 | 2025 | Vtama |
| Organogenesis INC. | $49.75 | 2023-2025 | Cygnus Dual, Puraply |
| Mayne Pharma Commercial LLC | $49.38 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $34.55 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $33.96 | 2022-2023 | Valchlor |
| Almirall LLC | $28.20 | 2021 | |
| Sandoz INC. | $26.02 | 2020 | |
| Springworks Therapeutics, INC. | $25.09 | 2025 | Gomekli |
| Mimedx Group, INC. | $24.61 | 2024 | |
| Verrica Pharmaceuticals INC. | $23.25 | 2023 | Ycanth |
| Amgen INC. | $19.91 | 2019 | |
| Vyne Pharmaceuticals INC. | $18.77 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.55 | 2022 | |
| Ucb, INC. | $15.69 | 2024 | Bimzelx |
| Biofrontera INC. | $15.06 | 2022 | |
| Aclaris Therapeutics, INC. | $13.02 | 2019 | |
| Mission Pharmacal Company | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rabb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.